Analyst Ratings for [HARP] Harpoon Therapeutics, Inc.

1/5/24	Initiated	Outperform	X
HARP Harpoon Therapeutics Oppenheimer
$23
11/20/23	Initiated	Outperform	X
HARP Harpoon Therapeutics TD Cowen
7/6/22	Resumed	Buy	X
HARP Harpoon Therapeutics Canaccord Genuity
$16
6/8/21	Downgrades	Buy Neutral	X
HARP Harpoon Therapeutics Citigroup
$25 $16
6/7/21	Downgrades	Outperform Neutral	X
HARP Harpoon Therapeutics Wedbush
5/28/21	Initiated	Overweight	X
HARP Harpoon Therapeutics Cantor Fitzgerald
$40
5/10/21	Initiated	Overweight	X
HARP Harpoon Therapeutics Piper Sandler
$35
12/23/20	Resumed	Buy	X
HARP Harpoon Therapeutics H.C. Wainwright
$31
5/24/19	Resumed	Buy	X
HARP Harpoon Therapeutics Citigroup
$23
4/23/19	Initiated	Outperform	X
HARP Harpoon Therapeutics Robert W. Baird
3/5/19	Initiated	Outperform	X
HARP Harpoon Therapeutics Wedbush
$23

HARP Harpoon Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.